Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Baxter
Boehringer Ingelheim
AstraZeneca
McKesson

Last Updated: October 13, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,871,631

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,871,631
Title:Methods of inhibiting the lowering of antihuman TNF-.alpha. antibody
Abstract: The present invention provides an antihuman TNF-.alpha. antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-.alpha. antibody; and a kit preparation wherein a freeze-dried antihuman TNF-.alpha. antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-.alpha. antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.
Inventor(s): Matsumoto; Takayuki (Fukuoka, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP)
Application Number:12/562,728
Patent Claims:1. A method of inhibiting the lowering of antihuman TNF-.alpha. antibody activity comprising administering to a subject suffering from inflammatory bowel disease that has or is undergoing a treatment regimen involving repeated administration of anti-TNF-.alpha. antibody an effective amount of a protein source(s), carbohydrate source(s) or a combination thereof, wherein the protein source(s) comprises the amino acids at least in the following contents by dry weight of the protein source(s): TABLE-US-00006 L-isoleucine 2.0 to 8.0 W/W % L-leucine 4.0 to 15.0 W/W % L-lysine 4.0 to 15.0 W/W % L-methionine 2.0 to 6.0 W/W % L-phenylalanine 4.0 to 12.0 W/W % L-threonine 1.0 to 8.0 W/W % L-triptophan 0.5 to 3.0 W/W % L-valine 2.0 to 6.0 W/W % L-histidine 1.0 to 8.0 W/W % L-arginine 5.0 to 9.0 W/W % L-alanine 4.0 to 8.0 W/W % L-asparaginic acid 2.0 to 15.0 W/W % L-glutamine 0 to 15.0 W/W % Glycin 1.0 to 12.0 W/W % L-proline 2.0 to 6.0 W/W % L-serine 1.0 to 10.0 W/W % L-tyrosine 0.1 to 3.0 W/W % L-cystein 0 to 10.0 W/W % L-glutaminic acid 0 to 10.0 W/W %,

and wherein the carbohydrate source(s) is at least one kind of sugar selected from the group consisting of glucose, fructose, maltose, sorbitol, xylitol and glycerin.

2. The method according to claim 1, wherein the protein source(s) is animal proteins, vegetable proteins or a combination thereof.

3. The method according to claim 1, wherein the protein source(s) is milk proteins, soybean protein isolates or a combination thereof.

4. The method according to claim 1, further comprising administering a lipid source(s).

5. The method according to claim 4, wherein the lipid source(s) comprises fats containing at least one kind of .omega.3 fatty acid(s), which is selected from the group consisting of .alpha.-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid.

6. The method according to claim 4, wherein the protein source(s), carbohydrate source(s), and lipid source(s) are administered in a single composition and said protein source(s) is in an amount of 5 to 30 W/W % by dry weight; the carbohydrate source(s) is in an amount of 40 to 90 W/W % by dry weight; and the lipid source(s) is in an amount of 0 to 30 W/W % by dry weight, wherein the weight percentage is relative to the total weight of same composition.

7. The method according to claim 6, wherein amounts of the protein source(s), the carbohydrate source(s) and the lipid source(s), relative to the total weight of the composition, are the following amounts by dry weight: TABLE-US-00007 Protein source(s); L-isoleucine 0.2 to 1.5 W/W % L-leucine 0.5 to 2.0 W/W % L-lysine 0.5 to 2.0 W/W % L-methionine 0.2 to 1.5 W/W % L-phenylalanine 0.5 to 2.0 W/W % L-threonine 0.2 to 1.5 W/W % L-triptophan 0.05 to 0.5 W/W % L-valine 0.2 to 1.5 W/W % L-histidine 0.5 to 2.0 W/W % L-arginine 0.5 to 2.5 W/W % L-alanine 0.5 to 2.0 W/W % L-asparaginic acid 1.0 to 4.0 W/W % L-glutamine 1.0 to 4.0 W/W % Glycin 0.2 to 1.5 W/W % L-proline 0.2 to 1.5 W/W % L-serine 0.5 to 2.5 W/W % L-tyrosine 0.05 to 0.5 W/W % Carbohydrate source(s); Dextrin 70 to 85 W/W % Lipid source(s); Soybean oil 0.1 to 10 W/W %.

8. The method according to claim 1, wherein the antihuman TNF-.alpha. antibody is a monoclonal antibody selected from the group consisting of a chimeric antibody, humanized antibody and human antibody.

9. The method according to claim 8, wherein the antihuman TNF-.alpha. antibody is at least one selected from the group consisting of Infliximab, Adalimumab and Etanercept.

10. The method according to claim 9, wherein the antihuman TNF-.alpha. antibody is Infliximab.

11. The method according to claim 1, wherein the inflammatory bowel disease is Crohn's disease.

12. The method according to claim 11, wherein the Crohn's disease is in the active stage and/or it accompanies the external fistula.

13. The method according to claim 1, wherein said administering further has an immune-deterioration-inhibiting effect, reduces concurrent infections or a combination thereof.

14. The method according to claim 1, wherein said administering is orally or enterally.

15. The method according to claim 1, wherein said administering is in the central vein.

Summary for Patent:   See Pricing

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-056343Mar 01, 2004

Details for Patent 7,871,631

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   See Pricing Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   See Pricing Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   See Pricing Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   See Pricing Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   See Pricing Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,871,631

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2005082377 Sep 09, 2005
United States of America 2006292148 Dec 28, 2006
United States of America 2010008916 Jan 14, 2010
United States of America 2010061999 Mar 11, 2010
United States of America 7638335 Dec 29, 2009
Japan 2012184249 Sep 27, 2012
Japan 5554466 Jul 23, 2014
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.